⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of City Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
City Therapeutics
↗Cambridge, United States
City Therapeutics is a privately held Cambridge, Massachusetts biotechnology company focused on next-generation RNA interference therapeutics. The company engineers small interfering RNA triggers, including cleavage-inducing tiny RNAs known as cityRNAs, and pairs them with precision targeting ligands intended to improve potency, specificity, durability, and delivery beyond the liver. Its stated objective is to create RNAi medicines across multiple therapeutic areas and previously inaccessible tissues. ([citytx.com](https://www.citytx.com/?utm_source=openai))
The company launched in October 2024 with a $135 million Series A led by ARCH Venture Partners. By June 2026, City had completed a $99.5 million Series B, bringing disclosed financing to approximately $234.5 million, and had expanded to approximately 75 employees. City is now a clinical-stage company with CITY-FXI in a Phase 1 study and CITY-RBP4 advancing toward the clinic, supported by strategic collaborations with Bausch + Lomb and Biogen. ([citytx.com](https://www.citytx.com/news/city-therapeutics-launches-with-135-million-series-a-financing-to-lead-the-future-of-rnai-based-medicine?utm_source=openai))
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:RNA therapeutics / RNA interference therapeutics
SIZE & FINANCIALS
Employees:51-200
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$234.5M disclosed
Investors:ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures, Viking Global Investors, Sofinnova Investments, Casdin Capital, NYBC Ventures, Other undisclosed investors
PIPELINE
Stage:Phase 1 and preclinical
Lead Drug Stage:Phase 1 - CITY-FXI
Modalities:Small interfering RNA, Cleavage-inducing tiny RNA / cityRNA, Engineered RNAi trigger molecules, Targeted ligand-conjugated RNAi, Extrahepatic RNAi delivery
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Bausch + Lomb - strategic collaboration to develop an RNAi treatment for retinal diseases including geographic atrophy; Bausch + Lomb may elect to advance a candidate through IND-enabling studies, clinical development, regulatory submissions, and commercialization., Biogen - strategic research collaboration combining City's RNAi engineering with Biogen's proprietary delivery technology for an undisclosed CNS target; Biogen is responsible for IND-enabling work, clinical development, regulatory submissions, manufacturing, and commercialization., The Ohio State University / Kotaro Nakanishi laboratory - publicly documented research support and scientific collaboration related to cityRNA and AGO3 biology.
COMPETITION
Position:Emerging
Competitors:Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Ionis Pharmaceuticals, ADARx Pharmaceuticals, Aro Biotherapeutics, Wave Life Sciences, Sarepta Therapeutics +2 more
LEADERSHIP
Key Executives:
Andy Orth - Chief Executive Officer
John Maraganore, PhD - Executive Chair and Co-founder
Baisong Mei, MD, PhD - Chief Medical Officer
Ari Nowacek, MD, PhD - Senior Vice President, Corporate Development
Anna O'Driscoll - Chief Human Resources Officer
Sebastian Trousil, PhD - Chief Operating Officer
Tracy Zimmermann, PhD - Chief Scientific Officer
Keith Regnante, MBA - Chief Financial Officer
Mary Beth DeLena, JD - Chief Legal Officer and Secretary
Scientific Founders:Mark Keating, MD, Kotaro Nakanishi, PhD, Yukihide Tomari, PhD, Phillip Zamore, PhD
Board Members:John Maraganore, PhD - Executive Chair, Andy Orth - Chief Executive Officer and Board Member, Barry Greene - Board Director, Robert Nelsen - Board Director and ARCH Venture Partners co-founder, Sara Nochur, PhD - Independent Board Director, Ron Philip - Board Director, Rohan Nirody - Board observer appointed in connection with the Series B financing, Maha Radhakrishnan, MD - Board observer appointed in connection with the Series B financing
LINKS
Website:citytx.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with City Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.